🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Please help us welcome Jonathon Parker to the Alto team as our SVP, Head of Regulatory Affairs! We are excited to have his leadership and #CNS expertise as we continue to advance our #PrecisionPsychiatry pipeline towards late-stage clinical development.

We’re heading to Toronto to present at the upcoming Society of Biological Psychiatry meeting. We look forward to sharing advancements that support our biomarker-driven pipeline for #neuropsychiatric conditions and deepen our neurobiological insights. More info here: bit.ly/3FUzjYk #SOBP2025

In a recent Citeline article, our CEO Amit Etkin discusses Alto's #PrecisionPsychiatry approach for the treatment of #neuropsychaitric conditions, guided by insights from #EEG, cognitive tests & wearable data. Read more: bit.ly/42BM4mB

We shared data from 6 poster presentations at #SOBP2025, highlighting biological & clinical insights that support our #PrecisionPsychiatry pipeline. Details: bit.ly/3GG1QE8

Are you attending the Jones Trading CNS Day? Our CEO, Amit Etkin will be participating in a fireside chat to discuss recent updates and advances towards #PrecisionPsychiatry. April 29, 2025 12:30 p.m. ET Find more information here: bit.ly/4lItGjk

Our work is featured in HCPLive showcasing how an #EEG biomarker can predict placebo response in #MDD clinical trials. These findings highlight the applications of this biomarker in #ClinicalTrials and potential to advance #PrecisionPsychiatry: bit.ly/4iIyp1K

#ICYMI, at #SOBP25 we presented findings from a study that identified and prospectively replicated an EEG-based biomarker for placebo response in #MajorDepressiveDisorder. To learn more, view the posters on Alto’s website here: bit.ly/3Z6usgb

Today, we reported our Q1 2025 financial results and key business highlights. Read more in our press release here: investors.altoneuroscience.com/news/news-deta… $ANRO

Our latest work is featured in Psychiatric Times showcasing new data presented at #SOBP2025. Check out the video interview series to learn more about the biological and clinical insights that support Alto’s #PrecisionPsychiatry pipeline. Part 2 here: psychiatrictimes.com/view/biomarker…

Today, our CEO, Amit Etkin, will participate in a panel discussion moderated by Ron Leuty at the Bay Area Biotech Forum, presented by San Francisco Business Times. Learn more about the event here: bizjournals.com/sanfrancisco/e… #SFBTbiotech

We presented data at #ASCP2025 that reinforces the unique biomarker opportunity for patient stratification, with strong mechanistic validation, and reinforces the tolerability profile for ALTO-300 in #MajorDepressiveDisorder. Learn more here: investors.altoneuroscience.com/news/news-deta… American Society of Clinical Pschopharm (ASCP)

Today we announced the acquisition of a novel dopamine agonist portfolio, adding a late-stage readout in treatment resistant depression within our current cash runway. We’re excited for the opportunity to advance this approach! Read more: investors.altoneuroscience.com/news/news-deta…

Are you attending the Jefferies Global Healthcare Conference? Our CEO, Amit Etkin will be participating in a fireside chat to discuss recent updates. #JefferiesHealthcare​ Tune in here: wsw.com/webcast/jeff31…

At this year’s Innovation in Psychosis Therapeutics Summit, our Chief Medical Officer, Adam Savitz, will join industry leaders in a panel discussion on the implementation of biomarkers for therapeutic advancement. Learn more about the event here: psychosis-therapeutics-summit.com

Excited to present at #BIO2025 in Boston, June 16-19! Our VP of Translational Medicine, Patricio O'Donnell, will join a panel discussion moderated by Rowan Walrath 😷 from C&EN (Chemical & Engineering News) on Precision in Practice. See you there! ​ Learn more about our session here: ​convention.bio.org/program-1/ve-e…

Tomorrow, our CEO, Amit Etkin will discuss Alto’s recent updates during a fireside chat at the H.C. Wainwright & Co. 6th Annual Neuro Perspectives Hybrid Conference. ​ The presentation will be available on-demand starting at 7:00 a.m. ET on June 17 here: journey.ct.events/view/874c298f-…

Meet Cherie Blaylock, Senior Director of Program Management here at Alto. Cherie is the force behind seamless cross-functional collaboration across our #PrecisionPsychaitry platform.

ICYMI, we were proud to join fellow leaders at #BIO2025 to discuss how precision medicine is redefining #psychiatry. Thank you to the organizers and everyone who attended our panel! ​ #PrecisionPsychiatry

We're excited to announce the identification of an #EEG biomarker and positive pharmacodynamic results from our exploratory Phase 2 proof-of-concept (POC) #ClinicalTrial of ALTO-203 in #MajorDepressiveDisorder patients with elevated levels of anhedonia. investors.altoneuroscience.com/news/news-deta…

We’re excited to highlight that data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD) were published online in The Lancet Psychiatry. Results from this study guided Alto’s acquisition of ALTO-207. Read more: investors.altoneuroscience.com/news/news-deta…